Poster Presentation GENEMAPPERS 2026

Assessing the genetic architecture of urinary metabolite concentrations using sbayesR (#114)

Harry McIntosh 1 , Enda Byrne 1 , Christel Middeldorp 1 , Harry McIntosh 1
  1. The University of Queensland, Indooroopilly, QUEENSLAND, Australia

Metabolites refer to any small molecules involved in metabolism as an intermediate or end product. Human metabolite concentrations can be assayed in blood, or less intrusively in urine. Urinary metabolites can reflect the function of biological pathways, including energy metabolism, diet, and amino-acid metabolism [1]. Metabolite concentrations have been implicated as biomarkers for physical and psychological health outcomes ranging from kidney disease to psychiatric disorders [2-6].

The concentrations of some metabolites are highly heritable, with previous research identifying hundreds of metabolite-gene associations [2, 7, 8]. Traits have distinct distributions of SNP effect sizes (genetic architectures) which influence the choice and performance of statistical methods. For example, methods such as LDSC regression assume a highly polygenic genetic architecture and may not be appropriate for traits with a more oligogenic architecture.

SbayesR is a statistical tool that uses Bayesian posterior inference and GWAS summary data to model trait architecture while simultaneously estimating SNP-based heritability [9]. We estimated the genetic architecture of 53 urinary metabolite concentrations in SbayesR using summary statistics from the current largest GWAS of urinary metabolites by Valo et al. (2025) [2].

We detected substantial variation in genetic architectures across the 53 urinary metabolites. Of the 29 metabolite concentrations with a detectable SNP-based heritability, 12 showed architectures dominated by fewer, large-effect SNPs. The remaining metabolites displayed more evenly spread (polygenic) SNP-effect distributions. Our SNP-based heritability estimates were generally lower than that of Valo et al.’s meta-analysis (except Taurine), likely reflecting the use of summary data as opposed to primary genotype data. Our posterior parameter estimates showed little sensitivity to model priors.

These results are informative for future genetic analyses of urinary metabolomic data and support previous evidence for large-effect loci for several metabolites [2].

  1. Mutter, S., et al., Urinary metabolite profiling and risk of progression of diabetic nephropathy in 2670 individuals with type 1 diabetes. Diabetologia, 2022. 65(1): p. 140-149.
  2. Valo, E., et al., Genome-wide characterization of 54 urinary metabolites reveals molecular impact of kidney function. Nat Commun, 2025. 16(1): p. 325.
  3. Likhitweerawong, N., et al., Profiles of urine and blood metabolomics in autism spectrum disorders. Metabolic Brain Disease, 2021. 36(7): p. 1641-1671.
  4. Wang, Y., et al., Metabolomics on depression: A comparison of clinical and animal research. Journal of Affective Disorders, 2024. 349: p. 559-568.
  5. Predescu, E., et al., Metabolomic Markers in Attention-Deficit/Hyperactivity Disorder (ADHD) among Children and Adolescents—A Systematic Review. International Journal of Molecular Sciences, 2024. 25(8): p. 4385.
  6. Mudra Rakshasa-Loots, A., et al., Metabolic psychiatry: key priorities for an emerging field. Nature Mental Health, 2025. 3(8): p. 855-858.
  7. Hagenbeek, F.A., et al., Heritability of Urinary Amines, Organic Acids, and Steroid Hormones in Children. Metabolites, 2022. 12(6).
  8. Sinnott-Armstrong, N., et al., Genetics of 35 blood and urine biomarkers in the UK Biobank. Nat Genet, 2021. 53(2): p. 185-194.
  9. Lloyd-Jones, L.R., et al., Improved polygenic prediction by Bayesian multiple regression on summary statistics. Nature Communications, 2019. 10(1): p. 5086.